We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00716963
First Posted: July 16, 2008
Last Update Posted: May 15, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Gail Gauvreau, McMaster University
July 14, 2008
July 16, 2008
April 14, 2015
May 15, 2015
May 15, 2015
July 2008
November 2008   (Final data collection date for primary outcome measure)
  • The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Fall in FEV1. [ Time Frame: Before inhalation 3 hours ]
  • The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Fall in FEV1. [ Time Frame: 7 hours after challenge ]
The magnitude of the late asthmatic response, expressed as a percentage change in FEV1 from baseline, and expressed as area under the curve. [ Time Frame: Before inhalation (0hrs), 3 hours, 7 hours after challenge ]
Complete list of historical versions of study NCT00716963 on ClinicalTrials.gov Archive Site
  • The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils). [ Time Frame: Before inhalation both evaluations (0 hours) ]
  • The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils) [ Time Frame: sputum @ 7 hours ]
  • The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils) [ Time Frame: 24 hours methacholine and sputum ]
The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils). [ Time Frame: Before inhalation both evaluations (0 hours), sputum @ 7 hours and @ 24 hours methacholine and sputum ]
Not Provided
Not Provided
 
Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?
Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction?
The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)

The aim of this pilot study is to evaluate whether fluticasone propionate affects the late allergic reaction after a single dose post-allergen challenge administered following cessation of the early allergic reaction.

Six subjects with mild asthma will be asked to volunteer for the study.The diagnosis of asthma will be and includes the presence of variable airflow limitation and AHR (PC20 methacholine < 16 mg/mL). Subjects will be asked to participate if they demonstrate an allergen-induced early and late asthmatic response of at least 20% and 15% reduction in FEV1, respectively.

The study will consist of 4 periods, composed of a screening allergen period with 3 subsequent allergen challenge/treatment periods. Each period will be separated with a washout of at least 2 weeks. Subjects who demonstrate a dual asthmatic response in the screening period will be selected for randomization to treatment.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Mild Asthma
  • Drug: Fluticasone propionate (Flovent Diskus) 250 mcg
    Flovent Diskus 250 mcg
    Other Name: fluticasone propionate Flovent Diskus250 mcg
  • Drug: budesonide 400 mcg
    budesonide 400 mcg
    Other Name: Pulmicort Turbuhaler 200 mcg
  • Other: Placebo
    Placebo
  • Active Comparator: 1
    Fluticasone propionate (Flovent Diskus) 250 mcg
    Intervention: Drug: Fluticasone propionate (Flovent Diskus) 250 mcg
  • Active Comparator: 2
    budesonide 400mcg
    Intervention: Drug: budesonide 400 mcg
  • Placebo Comparator: 3
    placebo
    Intervention: Other: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7
December 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • mild asthma
  • nonsmokers
  • allergen-induced early and late asthmatic response

Exclusion Criteria:

  • no medication other than infrequent ( < twice weekly) inhaled beta2-agonists
  • not be exposed to sensitizing allergens
  • asthma exacerbation or respiratory tract infection in the past4 weeks
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00716963
AZ2008lr
No
Not Provided
Not Provided
Gail Gauvreau, McMaster University
Hamilton Health Sciences Corporation
AstraZeneca
Principal Investigator: Paul O'Byrne, MD McMaster University
Study Director: Gail Gauvreau, PhD McMaster University
McMaster University
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP